Rapid Micro Biosystems, Inc. (NASDAQ:RPID) Q3 2024 Results Conference Call November 1, 2024 9:00 AM ET

Company Participants

Michael Beaulieu - CFA, VP, IR & Corporate Communications
Robert Spignesi - President & CEO
Sean Wirtjes - CFO

Conference Call Participants

Brendan Smith - TD Cowen
Dan Arias - Stifel

Operator

Thank you for standing by. My name is Novi, and I will be your conference operator today. At this time, I would like to welcome everyone to the Rapid Micro Biosystems Third Quarter 2024 Earnings Conference Call. All lines have been placed on mute to prevent any background noise. [Operator Instructions]. I would now like to turn the call over to Mike Beaulieu with Investor Relations. Please go ahead.

Michael Beaulieu

Good morning and thank you for joining the Rapid Micro Biosystems Q3 2024 earnings call. Joining me on the call are Rob Spignesi, President and Chief Executive Officer and Sean Wirtjes, Chief Financial Officer. Earlier today, we issued a press release announcing our Q3 2024 financial results. A copy of the release is available on the company's website at rapidmicrobio.com under Investors in the News and Events section.

Before we begin, I'd like to remind you that many statements made during this call may be considered forward looking statements within the meaning of federal securities laws, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995.

Any statements contained in this call that relate to expectations or predictions of future events, results or performance are forward-looking statements including but not limited to, statements relating to Rapid Micro's financial condition, assumptions regarding future financial performance, anticipated future cash usage and cash runway, guidance for 2024, including revenue, expenses, gross margins, system placements and validation activities, Rapid Micro's goal of achieving positive cash flow without additional financing and the timing thereof, expectations for and planned activities related to Rapid Micro's business development and growth, customer interest and adoption of the growth direct system and statements regarding Rapid sterility.

Actual results may differ materially from those expressed or implied in the forward-looking statements due to a variety of factors. For a list and description of the risks and uncertainties associated with Rapid Micro’s business, please refer to the risk factors section of our most recent quarterly report on Form 10-Q filed with the Securities and Exchange Commission as updated from time to time in our subsequent filings with the SEC. We urge you to consider these factors and you should be aware that these statements should be considered estimates only and are not a guarantee of financial future performance.